急性心衰患者连续ST2检测的预后价值
TRIUMPH队列纳入496例急性心衰患者,随访1年内重复采血7次,用联合模型评估ST2与全因死亡或心衰再住院复合终点的关联。校正临床因素与NT-proBNP后,基线ST2每升高1个标准差风险增加30%,考虑重复测量后风险增加85%,且ST2在终点事件前数周即升高。
要点
- 急性心衰中基线与重复ST2均与全因死亡/心衰再住院复合终点独立相关
- 校正重复NT-proBNP后ST2预后关联仍显著,重复测量时风险比更高
- ST2在事件前数周升高,或可用于预后判断与治疗监测
核心结论
- 连续ST2检测是急性心衰患者结局的强预测因子,且独立于重复测量的NT-proBNP,可能有助于临床预后判断与治疗监测。
研究设计与样本
- TRIUMPH临床队列研究,2009至2014年荷兰14家医院纳入496例急性心衰患者,1年随访期间重复采血7次,由中心实验室检测ST2与NT-proBNP,采用联合模型分析重复测量与主要终点的关联。
主要发现
- 中位随访325天(四分位距85至401)期间188例(40%)达到主要终点。
- 基线ST2中位71 ng/ml(四分位距46至102);校正临床因素与NT-proBNP后,基线ST2(log2尺度)每升高1个标准差的风险比1.30(95%CI 1.08至1.56;p=0.005)。
- 考虑重复测量并校正临床因素与重复NT-proBNP后,随访期间ST2(log2尺度)每升高1个标准差的风险比1.85(95%CI 1.02至3.33;p=0.044)。
- ST2水平在主要终点发生前数周出现升高。
临床怎么用
- 对急性心衰患者可考虑系列检测ST2,结合NT-proBNP用于预后分层与治疗监测。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Several clinical studies have evaluated the association between ST2 and outcome in patients with heart failure (HF). However, little is known about the predictive value of frequently measured ST2 levels in patients with acute HF. OBJECTIVES: This study sought to describe the prognostic value of baseline and repeated ST2 measurements in patients with acute HF. METHODS: In the TRIUMPH (Translational Initiative on Unique and novel strategies for Management of Patients with Heart failure) clinical cohort study, 496 patients with acute HF were enrolled in 14 hospitals in the Netherlands between 2009 and 2014. Repeated blood samples (7) were drawn during 1-year follow-up. ST2 and N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels were measured in a central laboratory. The primary endpoint was the composite of all-cause mortality and HF rehospitalization. Associations between repeated biomarker measurements and the primary endpoint were assessed using a joint model. RESULTS: Median age was 74 years, and 37% of patients were women. The primary endpoint was reached in 188 patients (40%) during a median follow-up of 325 days (interquartile range: 85 to 401). The median baseline ST2 level was 71 ng/ml (interquartile range: 46 to 102). After adjustment for clinical factors and NT-proBNP, baseline ST2 was associated with an increased risk of the primary endpoint, and the hazard ratio per 1 SD increase of the baseline ST2 level (on the log2 scale) was 1.30 (95% confidence interval: 1.08 to 1.56; p = 0.005). When repeated measurements were taken into account, the adjusted hazard ratio per 1 SD increase of the ST2 level (on the log2 scale) during follow-up increased to 1.85 (95% confidence interval: 1.02 to 3.33; p = 0.044), adjusted for clinical factors and repeated measurements of NT-proBNP. Furthermore, ST2 levels appeared to elevate several weeks before the time of the primary endpoint. CONCLUSIONS: Repeated ST2 measurements appeared to be a strong predictor of outcome in patients with acute HF, independent of repeatedly measured NT-proBNP. Hence ST2 may be helpful in clinical practice for prognostication and treatment monitoring. (TRanslational Initiative on Unique and novel strategies for Management of Patients with Heart failure [TRIUMPH]; NTR1893).
引用
- van Vark LC, Lesman-Leegte I, Baart SJ, et al. Prognostic Value of Serial ST2 Measurements in Patients With Acute Heart Failure. J Am Coll Cardiol. 2017. PMID: 29096809. doi:10.1016/j.jacc.2017.09.026
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。